Omeros Corporation

Cancer Research Technology Limited

Affitech Research As

Nextera As

Urs Beat Hagemann

Herald Reiersen

Thomas Dudler

Wayne Richard Gombotz

Anita Kavlie

Clark E Tedford

Sergej Kiprijanov

James Brian Parent

Remko Griep

Sergej Michailovic Kiprijanov

Geir Age Loset

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Compositions for inhibiting MASP-2 dependent complement activation

The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Antibodies which bind to the human CC chemokine receptor 4 and uses thereof

Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof

The present invention relates to a method for screening phage display libraries against each other. In particular, the invention relates to a method for screening at least two phage display libraries against each other to identify and/or select one or more interacting binding partners or binding molecules making up such interacting binding partners. Kits providing two bispecific phage display libraries are also provided.

Method for screening phage display libraries against each other

Growing community of inventors

Oslo, Norway

Urs Beat Hagemann